Stock GLMD GALMED PHARMACEUTICALS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Delayed Nasdaq
Other stock markets
 11:47:45 2024-07-09 am EDT 		5-day change 1st Jan Change
0.3015 USD +3.68% Intraday chart for Galmed Pharmaceuticals Ltd. +5.68% -33.74%
May. 30 Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 04 Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Galmed Pharmaceuticals : C/o Meitar Law Offices 16 Abba Hillel Silver Rd., Ramat Gan, 5250608 Form 6 K
PU
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis
CI
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
PR
Galmed Pharmaceuticals : Consolidated Financial Statements - Form 6-K
PU
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon
MT
Sector Update: Health Care
MT
Top Midday Decliners
MT
Galmed Pharmaceuticals Expects Minimum Six Months Delay in Primary Sclerosing Cholangitis Study
MT
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
PR
Galmed Pharmaceuticals Ltd. Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
CI
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
AQ
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
PR
Galmed Pharmaceuticals: Q2 Earnings Snapshot
AQ
Galmed Pharmaceuticals : 16 Tiomkin St. Tel Aviv 6578317, Israel - Form 6-K
PU
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Maxim Upgrades Galmed Pharmaceuticals to Buy From Hold, Price Target is $4
MT
Galmed Pharmaceuticals : Securities Purchase Agreement - Form 6-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GLMD Stock
  4. News Galmed Pharmaceuticals Ltd.